Ipsen S.A. (IPSEY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Boulogne-Billancourt, France. Der aktuelle CEO ist David Loew.
IPSEY hat IPO-Datum 2012-08-03, 5,358 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $64.99B.
Ipsen S.A. is a global biopharmaceutical company headquartered in France that develops and markets prescription drugs and consumer healthcare products across oncology, neuroscience, gastroenterology, and rare diseases. The company's oncology portfolio includes Cabometyx for renal cell and hepatocellular carcinoma, Onivyde for pancreatic cancer, and Cometriq for medullary thyroid cancer, while its specialty care offerings encompass Somatuline for neuroendocrine tumors, Dysport for neurological and aesthetic applications, and NutropinAq for growth hormone deficiency. Ipsen also maintains a significant gastroenterology and consumer healthcare business with products such as Smecta for diarrhea, Forlax for constipation, and Tanakan for cognitive disorders, along with established partnerships with leading biotechnology firms including Exelixis, Blueprint Medicines, and Galderma. Founded in 1929, the company leverages its diversified product portfolio and strategic collaborations to serve patients in multiple therapeutic areas worldwide.
